Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (ANTAMIN)
Pain Reduction for Limb Injuries in Pediatric Emergency Departments: A Randomised Clinical Trial Comparing Intranasal Fentanyl or Intranasal Ketamine to Oral Morphine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Hélène CHAPPUY, MD, PhD
- Phone Number: +33 1 44 49 41 26
- Email: helene.chappuy@aphp.fr
Study Contact Backup
- Name: Nelly BRIAND, PhD
- Phone Number: 0144381862
- Email: nelly.briand@aphp.fr
Study Locations
-
-
-
Boulogne-Billancourt, France, 92100
- Recruiting
- Ambroise Paré Hospital
-
Contact:
- Marlène MICHELON JOUNEAUX, MD, PhD
- Phone Number: 01 49 09 57 00
- Email: marlene.michelonjouneaux@aphp.fr
-
Principal Investigator:
- Marlène MICHELON JOUNEAUX
-
Lille, France, 59000
- Recruiting
- Roger Salengro Hospital
-
Contact:
- Melany LIBER, MD, PhD
- Phone Number: +33 03 20 44 46 64
- Email: melany.liber@chu-lille.fr
-
Principal Investigator:
- Melany LIBER
-
Marseille, France, 13005
- Recruiting
- Timone Hospital
-
Contact:
- Aurélie MORAND, MD, PHD
- Phone Number: +33 04 91 38 96 99
- Email: aurelie.morand@ap-hm.fr
-
Principal Investigator:
- Aurélie MORAND
-
Nantes, France, 44000
- Recruiting
- Mère-Enfant Hospital
-
Contact:
- Adeline BOUCHERON
- Phone Number: +33 02 44 76 84 79
- Email: adeline.boucheron@chu-lille.fr
-
Principal Investigator:
- Adeline BOUCHERON
-
Paris, France, 75015
- Recruiting
- Hôpital Necker Enfants malades
-
Contact:
- Hélène CHAPPUY, MD, PhD
- Phone Number: +33 +33 1 44 49 41 26
- Email: helene.chappuy@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child aged 2 years to 17 years and 11 months
- With 10 kg ≤ Weight ≤ 100 kg
- Presenting to ED with a traumatic pain and suspected fracture(s) based on an acute deformity AND experiencing pain and/or functional impotence in the injured limb(s)
- Within the first 12 hours after the injury
- VAS pain score at ED arrival ≥ 60/100 (if child ≥ 7 years) or Evendol pain score at ED arrival ≥ 7/15 (if child < 7 years)
- Affiliated to health insurance
- At least one signed parental informed consent
Exclusion Criteria:
- Received narcotic pain medication prior to arrival
- Contraindication to morphine, mentioned in SmPC
- Hypersensitivity to ketamine or fentanyl or to excipients (sodium chloride, sodium hydroxide), or to other opioids.
- Contraindication to fentanyl or ketamine, mentioned in SmPC
- GCS <15
- Evidence of significant femur, head, chest, abdominal, or spine injury
- Open fracture
- Nasal trauma or complete nasal obstruction
- Active epistaxis
- Nasal or sinus surgery within 6 months before inclusion
- History of high blood pressure, known coronary artery disease, congestive heart failure, acute glaucoma, increased intracranial pressure, major psychiatric disorder, hepatocellular insufficiency
- Active or history of psychiatric disorder
- Known pregnancy or suspicion of being pregnant
- Breastfeeding
- Non-French speaking parent and / or child.
- Participation to another interventional clinical research
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Morphine
Oral morphine (0.5mg/kg) and IN placebo
|
oral morphine (0.5 mg / kg)
Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
|
|
Experimental: IN Fentanyl
placebo of oral morphine and IN fentanyl (1.5 µg/kg)
|
Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
IN fentanyl (1.5 µg/kg)
|
|
Experimental: IN Ketamin
placebo of oral morphine and IN ketamine (1 mg/kg)
|
Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
IN ketamine (1 mg/kg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of pain (M30)
Time Frame: 30 minutes
|
Success: children <7 years with a pain score assessed by Evendol < 5 years, 30 minutes after drugs administration, without rescue analgesia.
Scale: 0-15 (no pain - painful)
|
30 minutes
|
|
Degree of pain (M30)
Time Frame: 30 minutes
|
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 30 minutes after drugs administration, without rescue analgesia.
Visual Analog Scale : 0-100 (no pain- painful)
|
30 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of pain (M15)
Time Frame: 15 minutes
|
Success: children <7 years with a pain score assessed by Evendol < 5, 15 minutes after drugs administration, without rescue analgesia
|
15 minutes
|
|
Degree of pain (M15)
Time Frame: 15 minutes
|
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 15 minutes after drugs administration, without rescue analgesia
|
15 minutes
|
|
Degree of pain (M60)
Time Frame: 60 minutes
|
Success: children <7 years with a pain score assessed by Evendol < 5, 60 minutes after drugs administration, without rescue analgesia
|
60 minutes
|
|
Degree of pain (M60)
Time Frame: 60 minutes
|
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 60 minutes after drugs administration, without rescue analgesia
|
60 minutes
|
|
Degree of pain (M90)
Time Frame: 90 minutes
|
Success: children <7 years with a pain score assessed by Evendol < 5, 90 minutes after drugs administration, without rescue analgesia
|
90 minutes
|
|
Degree of pain (M90)
Time Frame: 90 minutes
|
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 90 minutes after drugs administration, without rescue analgesia
|
90 minutes
|
|
Degree of pain (M120)
Time Frame: 120 minutes
|
Success: children <7 years with a pain score assessed by Evendol < 5, 120 minutes after drugs administration, without rescue analgesia
|
120 minutes
|
|
Degree of pain (M120)
Time Frame: 120 minutes
|
Success: children ≥ 7 years with pain score assessed by VAS ≤ 30, 120 minutes after drugs administration, without rescue analgesia
|
120 minutes
|
|
Reduction in pain (M15)
Time Frame: 15 minutes
|
Reduction in pain from baseline assessed by Evendol for children <7 years
|
15 minutes
|
|
Reduction in pain (M15)
Time Frame: 15 minutes
|
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
|
15 minutes
|
|
Reduction in pain (M30)
Time Frame: 30 minutes
|
Reduction in pain from baseline assessed by Evendol for children <7 years
|
30 minutes
|
|
Reduction in pain (M30)
Time Frame: 30 minutes
|
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
|
30 minutes
|
|
Reduction in pain (M60)
Time Frame: 60 minutes
|
Reduction in pain from baseline assessed by Evendol for children <7 years
|
60 minutes
|
|
Reduction in pain (M60)
Time Frame: 60 minutes
|
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
|
60 minutes
|
|
Reduction in pain (M90)
Time Frame: 90 minutes
|
Reduction in pain from baseline assessed by Evendol for children <7 years
|
90 minutes
|
|
Degree of pain (M30) for comparison ketamine vs fentanyl
Time Frame: 30 minutes
|
Success pain evaluation, as defined in primary outcome (for the comparison between ketamine and fentanyl) assessed by Evendol for children <7 years
|
30 minutes
|
|
Degree of pain (M30) for comparison ketamine vs fentanyl
Time Frame: 30 minutes
|
Success pain evaluation, as defined in primary outcome (for the comparison between ketamine and fentanyl) assessed by VAS for children ≥ 7 years
|
30 minutes
|
|
Level of sedation (M5)
Time Frame: 5 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
5 minutes
|
|
Level of sedation (M10)
Time Frame: 10 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
10 minutes
|
|
Level of sedation (M15)
Time Frame: 15 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
15 minutes
|
|
Level of sedation (M30)
Time Frame: 30 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
30 minutes
|
|
Level of sedation (M60)
Time Frame: 60 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
60 minutes
|
|
Level of sedation (M90)
Time Frame: 90 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
90 minutes
|
|
Level of sedation (M120)
Time Frame: 120 minutes
|
Level of sedation as measured by the University of Michigan Sedation Scale Score (UMSS) after drugs administration, from 0 (patient awake) to 4 (patient unawakable)
|
120 minutes
|
|
Number of participants with Adverse events
Time Frame: From study treatment intake until ED discharge, up to 1 day
|
Adverse events potentially associated with IN ketamine, IN fentanyl and/or oral morphine: drowsiness, dizziness, pruritus, nausea, vomiting, dysphoria, nasal burning and irritation, unpleasant taste, vision changes, throat irritation, headache, vital sign changes (heart rate, respiratory rate, oxygen saturation, blood pressure).
|
From study treatment intake until ED discharge, up to 1 day
|
|
Score of satisfaction
Time Frame: At ED discharge, up to 1 day
|
General satisfaction of parents and patient ≥ 7 years old on a scale of 0-100 with corresponding faces (0 = no satisfaction at all, 100 = very satisfied)
|
At ED discharge, up to 1 day
|
|
Reduction in pain (M90)
Time Frame: 90 minutes
|
Reduction in pain from baseline (assessed by VAS for children ≥ 7 years)
|
90 minutes
|
|
Reduction in pain (M120)
Time Frame: 120 minutes
|
Reduction in pain from baseline assessed by VAS for children ≥ 7 years
|
120 minutes
|
|
Reduction in pain (M120)
Time Frame: 120 minutes
|
Reduction in pain from baseline assessed by EVENDOL for children < 7 years
|
120 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Hélène CHAPPUY, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Alkaloids
- Polycyclic Aromatic Hydrocarbons
- Polycyclic Compounds
- Piperidines
- Heterocyclic Compounds, 4 or More Rings
- Morphinans
- Opiate Alkaloids
- Heterocyclic Compounds, Bridged-Ring
- Phenanthrenes
- Morphine Derivatives
- Morphine
- Ketamine
- Fentanyl
Other Study ID Numbers
Other Study ID Numbers
- APHP211044
- 2023-506803-25 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.